Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis

Hartmut H. Malluche, Daniel L. Davenport, Tom Canto, Marie Claude Monier-Faugere

Research output: Contribution to journalArticlepeer-review

110 Scopus citations

Abstract

Background and objectives Use of bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA) is controversial for diagnosing bone loss in CKD patients on dialysis. The alternative quantitative computed tomography (QCT) is expensive and requires high radiation exposure. This study compared the two techniques and evaluated serum biochemical parameters for prediction of bone loss. Design, setting, participants, & measurements This prospective study enrolled patients from dialysis centers throughout Kentucky. BMD of the spine and hip was measured at baseline and after 1 year by DXA and QCT. Customary and novel serum biochemical parameters were obtained at the same times, including calcium, phosphorus, whole and intact parathyroid hormone, bone-specific alkaline phosphatase, procollagen type 1 N-terminal propeptide, tartrate-resistant acid phosphatase-5b, Dickkopf-1, fibroblast growth factor, and sclerostin. Rates of detection of osteoporosis by DXA and QCT were compared. Correlations were calculated between baseline biochemical parameters and BMDat baseline and changes over 1 year.Multivariable regression was performed to adjust for age, sex, body mass index, and race. Results Eighty-one patients completed the study (mean age=52.6±12.3 years, 56% men, 53% African American, and median dialysis vintage=41 months). At baseline, QCT and DXA of the spine identified similar rates of osteoporosis (13.6% and 13.6%), but at the hip, DXA identified more osteoporosis (22.2% versus 13.6%). At any site and by eithermethod, 33.3%of the patientswere osteoporotic. Baseline BMDcorrelatedwith sclerostin, intact parathyroid hormone, bone-specific alkaline phosphatase, tartrate-resistant acid phosphatase-5b, and fibroblast growth factor.At 1 year, hipQCT identified a higher number of patients experiencing bone loss (51.3%) than DXA (38.5%). ftermultivariable adjustment, baseline sclerostin and tartrate-resistant acid phosphatase-5b predicted bone loss measured by QCT of the hip; procollagen type 1 N-terminal propeptide predicted cortical spine bone gain by QCT. Conclusions QCT identified prospectively more bone loss at the hip than DXA.

Original languageEnglish
Pages (from-to)1254-1262
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Volume9
Issue number7
DOIs
StatePublished - 2014

Bibliographical note

Publisher Copyright:
© 2014 by the American Society of Nephrology.

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Fingerprint

Dive into the research topics of 'Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis'. Together they form a unique fingerprint.

Cite this